Venturi Wealth Management LLC Acquires 6,320 Shares of Avantor, Inc. (NYSE:AVTR)

Venturi Wealth Management LLC boosted its holdings in shares of Avantor, Inc. (NYSE:AVTR) by 504.8% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 7,572 shares of the company’s stock after buying an additional 6,320 shares during the period. Venturi Wealth Management LLC’s holdings in Avantor were worth $160,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in AVTR. State Street Corp boosted its stake in Avantor by 58.0% during the third quarter. State Street Corp now owns 22,368,244 shares of the company’s stock valued at $578,666,000 after buying an additional 8,206,695 shares during the period. The Manufacturers Life Insurance Company raised its position in Avantor by 653.0% during the third quarter. The Manufacturers Life Insurance Company now owns 6,174,736 shares of the company’s stock valued at $159,740,000 after purchasing an additional 5,354,678 shares in the last quarter. FMR LLC raised its position in Avantor by 557.2% during the third quarter. FMR LLC now owns 4,675,283 shares of the company’s stock valued at $120,950,000 after purchasing an additional 3,963,912 shares in the last quarter. Janus Henderson Group PLC raised its position in Avantor by 18.2% during the third quarter. Janus Henderson Group PLC now owns 17,692,705 shares of the company’s stock valued at $457,710,000 after purchasing an additional 2,719,615 shares in the last quarter. Finally, Principal Financial Group Inc. raised its position in Avantor by 146.5% during the third quarter. Principal Financial Group Inc. now owns 2,628,372 shares of the company’s stock valued at $67,996,000 after purchasing an additional 1,562,018 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on AVTR. Raymond James restated an “outperform” rating and set a $24.00 price target (down previously from $26.00) on shares of Avantor in a research report on Monday, February 10th. Royal Bank of Canada lowered their price target on Avantor from $33.00 to $31.00 and set an “outperform” rating on the stock in a research report on Monday, February 10th. Robert W. Baird lowered their price target on Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research report on Monday, October 28th. UBS Group restated a “neutral” rating and set a $25.00 price target (down previously from $29.00) on shares of Avantor in a research report on Friday, January 17th. Finally, Stifel Nicolaus lowered their price target on Avantor from $28.00 to $26.00 and set a “buy” rating on the stock in a research report on Monday, February 10th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.92.

Avantor Trading Down 1.1 %

NYSE AVTR opened at $17.31 on Friday. Avantor, Inc. has a 1-year low of $17.14 and a 1-year high of $28.00. The company has a current ratio of 1.07, a quick ratio of 0.70 and a debt-to-equity ratio of 0.54. The stock has a 50-day moving average of $20.96 and a 200-day moving average of $22.95. The firm has a market cap of $11.78 billion, a PE ratio of 16.64, a price-to-earnings-growth ratio of 1.59 and a beta of 1.28.

Avantor (NYSE:AVTR) last released its earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.01. Avantor had a return on equity of 12.17% and a net margin of 10.49%. During the same period last year, the firm posted $0.22 earnings per share. As a group, sell-side analysts forecast that Avantor, Inc. will post 1.06 EPS for the current year.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.